Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Activin type II receptor signaling in cardiac aging and heart failure.

Roh JD, Hobson R, Chaudhari V, Quintero P, Yeri A, Benson M, Xiao C, Zlotoff D, Bezzerides V, Houstis N, Platt C, Damilano F, Lindman BR, Elmariah S, Biersmith M, Lee SJ, Seidman CE, Seidman JG, Gerszten RE, Lach-Trifilieff E, Glass DJ, Rosenzweig A.

Sci Transl Med. 2019 Mar 6;11(482). pii: eaau8680. doi: 10.1126/scitranslmed.aau8680.

PMID:
30842316
2.

Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β 2-Adrenoceptor Agonist with Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular Safety Window in Preclinical Studies.

Koziczak-Holbro M, Rigel DF, Dumotier B, Sykes DA, Tsao J, Nguyen NH, Bösch J, Jourdain M, Flotte L, Adachi Y, Kiffe M, Azria M, Fairhurst RA, Charlton SJ, Richardson BP, Lach-Trifilieff E, Glass DJ, Ullrich T, Hatakeyama S.

J Pharmacol Exp Ther. 2019 May;369(2):188-199. doi: 10.1124/jpet.118.255307. Epub 2019 Feb 28.

PMID:
30819762
3.

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS.

Am J Respir Crit Care Med. 2019 Feb 1;199(3):313-320. doi: 10.1164/rccm.201802-0286OC.

4.

Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15.

Jones JE, Cadena SM, Gong C, Wang X, Chen Z, Wang SX, Vickers C, Chen H, Lach-Trifilieff E, Hadcock JR, Glass DJ.

Cell Rep. 2018 Mar 20;22(12):3375. doi: 10.1016/j.celrep.2018.03.024. No abstract available.

5.

Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15.

Jones JE, Cadena SM, Gong C, Wang X, Chen Z, Wang SX, Vickers C, Chen H, Lach-Trifilieff E, Hadcock JR, Glass DJ.

Cell Rep. 2018 Feb 6;22(6):1522-1530. doi: 10.1016/j.celrep.2018.01.044. Erratum in: Cell Rep. 2018 Mar 20;22(12 ):3375.

6.

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.

Morvan F, Rondeau JM, Zou C, Minetti G, Scheufler C, Scharenberg M, Jacobi C, Brebbia P, Ritter V, Toussaint G, Koelbing C, Leber X, Schilb A, Witte F, Lehmann S, Koch E, Geisse S, Glass DJ, Lach-Trifilieff E.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12448-12453. doi: 10.1073/pnas.1707925114. Epub 2017 Nov 6.

7.

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.

Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R.

J Am Geriatr Soc. 2017 Sep;65(9):1988-1995. doi: 10.1111/jgs.14927. Epub 2017 Jun 27.

PMID:
28653345
8.

ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.

Hatakeyama S, Summermatter S, Jourdain M, Melly S, Minetti GC, Lach-Trifilieff E.

Skelet Muscle. 2016 Jul 26;6:26. doi: 10.1186/s13395-016-0098-2. eCollection 2016.

9.

GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.

Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, Mallozzi C, Jacobi C, Jennings LL, Clay I, Laurent G, Ma S, Brachat S, Lach-Trifilieff E, Shavlakadze T, Trendelenburg AU, Brack AS, Glass DJ.

Cell Metab. 2015 Jul 7;22(1):164-74. doi: 10.1016/j.cmet.2015.05.010. Epub 2015 May 19.

10.

Treatment of sporadic inclusion body myositis with bimagrumab.

Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA.

Neurology. 2014 Dec 9;83(24):2239-46. doi: 10.1212/WNL.0000000000001070. Epub 2014 Nov 7.

11.

An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.

Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, Hatakeyama S, Glass DJ.

Mol Cell Biol. 2014 Feb;34(4):606-18. doi: 10.1128/MCB.01307-13. Epub 2013 Dec 2.

12.

Genomic profiling reveals that transient adipogenic activation is a hallmark of mouse models of skeletal muscle regeneration.

Lukjanenko L, Brachat S, Pierrel E, Lach-Trifilieff E, Feige JN.

PLoS One. 2013 Aug 15;8(8):e71084. doi: 10.1371/journal.pone.0071084. eCollection 2013.

13.

Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism.

Fournier B, Murray B, Gutzwiller S, Marcaletti S, Marcellin D, Bergling S, Brachat S, Persohn E, Pierrel E, Bombard F, Hatakeyama S, Trendelenburg AU, Morvan F, Richardson B, Glass DJ, Lach-Trifilieff E, Feige JN.

Mol Cell Biol. 2012 Jul;32(14):2871-9. doi: 10.1128/MCB.06575-11. Epub 2012 May 14.

14.

The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice.

Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, Makonchuk DY, Glass DJ, Kumar A.

J Cell Biol. 2010 Mar 22;188(6):833-49. doi: 10.1083/jcb.200909117.

15.

The mechanism of loss of CR1 during maturation of erythrocytes is different between factor I deficient patients and healthy donors.

Miot S, Marfurt J, Lach-Trifilieff E, González-Rubio C, López-Trascasa M, Sadallah S, Schifferli JA.

Blood Cells Mol Dis. 2002 Sep-Oct;29(2):200-12.

PMID:
12490287
16.

In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide.

Lach-Trifilieff E, McKay RA, Monia BP, Karras JG, Walker C.

Am J Respir Cell Mol Biol. 2001 Feb;24(2):116-22.

PMID:
11159044
17.

Syk-deficient eosinophils show normal interleukin-5-mediated differentiation, maturation, and survival but no longer respond to FcgammaR activation.

Lach-Trifilieff E, Menear K, Schweighoffer E, Tybulewicz VL, Walker C.

Blood. 2000 Oct 1;96(7):2506-10.

18.

Complement receptor 1 (CD35) on human reticulocytes: normal expression in systemic lupus erythematosus and HIV-infected patients.

Lach-Trifilieff E, Marfurt J, Schwarz S, Sadallah S, Schifferli JA.

J Immunol. 1999 Jun 15;162(12):7549-54.

Supplemental Content

Loading ...
Support Center